ATE135918T1 - Verbesserte vakzinzusammensetzung - Google Patents

Verbesserte vakzinzusammensetzung

Info

Publication number
ATE135918T1
ATE135918T1 AT91915418T AT91915418T ATE135918T1 AT E135918 T1 ATE135918 T1 AT E135918T1 AT 91915418 T AT91915418 T AT 91915418T AT 91915418 T AT91915418 T AT 91915418T AT E135918 T1 ATE135918 T1 AT E135918T1
Authority
AT
Austria
Prior art keywords
improved vaccine
vaccine composition
compositions
immunoadjuvant
immunogen
Prior art date
Application number
AT91915418T
Other languages
English (en)
Inventor
Christopher L Penney
Francis Michon
Harold J Jennings
Original Assignee
North American Vaccine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by North American Vaccine Inc filed Critical North American Vaccine Inc
Application granted granted Critical
Publication of ATE135918T1 publication Critical patent/ATE135918T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AT91915418T 1990-09-17 1991-09-12 Verbesserte vakzinzusammensetzung ATE135918T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US58337290A 1990-09-17 1990-09-17

Publications (1)

Publication Number Publication Date
ATE135918T1 true ATE135918T1 (de) 1996-04-15

Family

ID=24332852

Family Applications (1)

Application Number Title Priority Date Filing Date
AT91915418T ATE135918T1 (de) 1990-09-17 1991-09-12 Verbesserte vakzinzusammensetzung

Country Status (28)

Country Link
US (1) US5773007A (de)
EP (1) EP0549617B1 (de)
JP (1) JPH06500772A (de)
CN (1) CN1060408A (de)
AT (1) ATE135918T1 (de)
AU (1) AU8441991A (de)
BR (1) BR9106853A (de)
CA (1) CA2090673A1 (de)
CS (1) CS283991A3 (de)
CZ (1) CZ42993A3 (de)
DE (1) DE69118389T2 (de)
DK (1) DK0549617T3 (de)
ES (1) ES2084827T3 (de)
FI (1) FI931169A (de)
GR (1) GR3020117T3 (de)
HR (1) HRP920874A2 (de)
HU (1) HUT64237A (de)
IE (1) IE913261A1 (de)
IL (1) IL99403A0 (de)
IS (1) IS3753A7 (de)
MX (1) MX9101077A (de)
NO (1) NO930938D0 (de)
NZ (1) NZ239643A (de)
OA (1) OA09776A (de)
SK (1) SK18693A3 (de)
WO (1) WO1992004915A1 (de)
YU (1) YU153291A (de)
ZA (1) ZA917356B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE1008977A5 (fr) * 1994-12-27 1996-10-01 Solvay Adjuvants pour vaccins.
US5866132A (en) * 1995-06-07 1999-02-02 Alberta Research Council Immunogenic oligosaccharide compositions
US5695768A (en) 1995-06-07 1997-12-09 Alberta Research Council Immunostimulating activity of Streptococcus pneumoniae serotype 8 oligosaccharides
EP1018877A4 (de) * 1995-10-17 2000-08-09 Dovetail Technologies Inc Zell-, knochenmark- und immunistimulanzen mit niedrigerm molekulargewicht
HUP9901039A2 (hu) * 1996-02-01 1999-07-28 North American Vaccine, Inc. Neisseria meningitidis B-csoportba tartozó külső-membrán-fehérjéjének (MB3) expressziója élesztőben, továbbá vakcinák
US6299881B1 (en) * 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20080050367A1 (en) * 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6787523B1 (en) * 1997-12-02 2004-09-07 Neuralab Limited Prevention and treatment of amyloidogenic disease
EP2226336B1 (de) 1997-12-23 2016-10-19 Pfizer Ireland Pharmaceuticals Bakterielle Kapsel-Polysaccharide für die Verwendung als Impfstoffe oder als Impfstoffe-Konjugat
US20050059802A1 (en) * 1998-04-07 2005-03-17 Neuralab Ltd Prevention and treatment of amyloidogenic disease
AU767047B2 (en) * 1998-07-20 2003-10-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Vaccines against (escherichia coli) O157 infection
US6858211B1 (en) * 1998-07-20 2005-02-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccines against Escherichia coli O157 infection
US9134303B1 (en) 1998-08-25 2015-09-15 Alere Scarborough, Inc. ICT immunoassay for Legionella pneumophila serogroup 1 antigen employing affinity purified antibodies thereto
US6824997B1 (en) 1998-09-18 2004-11-30 Binax, Inc. Process and materials for the rapid detection of streptococcus pneumoniae employing purified antigen-specific antibodies
US20080096236A1 (en) * 1998-08-25 2008-04-24 Binax, Inc. Method for Detecting the Presence of Target Bacteria or a Target Component Carbohydrate Antigen Thereof
US6146902A (en) * 1998-12-29 2000-11-14 Aventis Pasteur, Inc. Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions
PL203917B1 (pl) * 1999-03-19 2009-11-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna, sposób jej wytwarzania oraz zastosowanie
UA81216C2 (en) * 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
CA2435681C (en) * 2001-01-23 2011-06-21 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
AU2002309706A1 (en) * 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
US7534442B2 (en) * 2001-08-21 2009-05-19 The Brigham And Women's Hospital, Inc. Immunogenic compositions comprising covalently bound polysaccharides, antigen, and bacterial toxoid
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2004069182A2 (en) * 2003-02-01 2004-08-19 Neuralab Limited Active immunization to generate antibodies to soluble a-beta
US8048432B2 (en) 2003-08-06 2011-11-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Polysaccharide-protein conjugate vaccines
EP1651261B1 (de) * 2003-08-06 2014-10-08 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Polysaccharid-protein-konjugat-vakzine
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
WO2007116409A2 (en) * 2006-04-11 2007-10-18 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Improved vaccines comprising multimeric hsp60 peptide carriers
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
PL2182983T3 (pl) * 2007-07-27 2014-10-31 Janssen Alzheimer Immunotherap Leczenie chorób amyloidowych z wykorzystaniem humanizowanych przeciwciał specyficznych względem Abeta
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
EP3263128A3 (de) * 2009-04-14 2018-01-24 GlaxoSmithKline Biologicals S.A. Zusammensetzungen zur immunisierung gegen staphylococcus aureus
US8003112B2 (en) * 2009-04-16 2011-08-23 Howard University Meningococcal and pneumococcal conjugate vaccine and method of using same
SG10201406432RA (en) 2009-06-22 2014-11-27 Wyeth Llc Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
EP2890395A1 (de) * 2012-08-31 2015-07-08 Novartis AG Stabilisierte proteine zur immunisierung gegen staphylococcus aureus
CN102839159B (zh) * 2012-09-07 2014-03-19 江苏康淮生物科技有限公司 一种CoxA16病毒株和人用CoxA16灭活疫苗
CN106606775A (zh) * 2015-10-27 2017-05-03 格里菲斯大学 脂质体a群链球菌疫苗
EP3493840B1 (de) * 2016-08-05 2022-08-24 Sanofi Pasteur Inc. Polyvalente pneumokokken-polysaccharid-proteinkonjugatzusammensetzung
EP3678654A4 (de) 2017-09-07 2021-04-21 Merck Sharp & Dohme Corp. Pneumokokken-polysaccharide und deren verwendung in immunogenen polysaccharid-trägerproteinkonjugaten
KR102486891B1 (ko) 2018-02-05 2023-01-10 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
CA3096358A1 (en) 2018-04-18 2019-10-24 Sk Bioscience Co., Ltd. Streptococcus pneumoniae capsular polysaccharide and immunogenic conjugate thereof
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1138773A (en) * 1979-04-18 1983-01-04 George Wojcik Synthetic adjuvants for stimulation of antigenic responses
US4258029A (en) * 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
US5019383A (en) * 1981-01-09 1991-05-28 New York Blood Center, Inc. Fatty acid carriers for synthetic peptides
EP0064366A1 (de) * 1981-04-29 1982-11-10 Beecham Group Plc Pharmazeutische Zusammensetzungen
US4663160A (en) * 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) * 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4639371A (en) * 1984-10-02 1987-01-27 New York Blood Center, Inc. Hepatitis B antigenic compositions and vaccines against hepatitis B derived therefrom
JPH0832637B2 (ja) * 1985-02-14 1996-03-29 アクゾ・エヌ・ヴエー 合成免疫原
US4863735A (en) * 1985-02-19 1989-09-05 Massachusetts Institute Of Technology Biodegradable polymeric drug delivery system with adjuvant activity
FR2581877B1 (fr) * 1985-05-14 1987-12-18 Louvain Universite Catholique Conjugue constitue d'une adhesine de paroi de s. mutans, de nature proteique et d'un polysaccharide de s. mutans, sa preparation et son utilisation notamment dans des vaccins anti-caries
DK163176C (da) * 1985-09-27 1992-06-22 Schweiz Serum & Impfinst Ugiftig konjugatvaccine mod infektioner af pseudomonas aeruginosa- og escherichia coli- bakterier, fremgangsmaade til fremstilling heraf og anvendelse af vaccinen
US4727136A (en) * 1985-10-01 1988-02-23 Canadian Patents And Development Ltd. Modified meningococcal group B polysaccharide for conjugate vaccine
ATE60999T1 (de) * 1986-12-19 1991-03-15 Duphar Int Res Dimethyldioctadecylammoniumbromid enthaltende stabilisierte adjuvanssuspension.
NZ223009A (en) * 1986-12-31 1990-06-26 Nl Rivm Of Thoven Oligosaccharides containing d-ribose d-ribitol and phosphate units mimicing haemophilus influenzae type b antigens
CA1329124C (en) * 1987-02-02 1994-05-03 Jerald C. Sadoff Conjugate malaria vaccine
GB8807860D0 (en) * 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
NZ230424A (en) * 1988-08-25 1992-05-26 Liposome Co Inc Liposomal composition comprising an externally disposed antigen
AU640118B2 (en) * 1988-12-19 1993-08-19 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Meningococcal class 1 outer-membrane protein vaccine

Also Published As

Publication number Publication date
IE913261A1 (en) 1992-02-25
FI931169A0 (fi) 1993-03-16
DK0549617T3 (da) 1996-04-22
MX9101077A (es) 1992-05-04
US5773007A (en) 1998-06-30
CZ42993A3 (en) 1994-04-13
YU153291A (sh) 1994-06-24
NO930938L (no) 1993-03-16
FI931169A (fi) 1993-04-22
NZ239643A (en) 1996-05-28
IL99403A0 (en) 1992-08-18
CN1060408A (zh) 1992-04-22
ES2084827T3 (es) 1996-05-16
IS3753A7 (is) 1992-03-18
JPH06500772A (ja) 1994-01-27
OA09776A (en) 1993-11-30
NO930938D0 (no) 1993-03-16
CA2090673A1 (en) 1992-03-18
HRP920874A2 (en) 1996-04-30
EP0549617A1 (de) 1993-07-07
AU8441991A (en) 1992-04-15
HU9300746D0 (en) 1993-06-28
BR9106853A (pt) 1993-08-17
GR3020117T3 (en) 1996-08-31
ZA917356B (en) 1992-09-30
SK18693A3 (en) 1993-08-11
HUT64237A (en) 1993-12-28
CS283991A3 (en) 1992-04-15
DE69118389T2 (de) 1996-08-29
WO1992004915A1 (en) 1992-04-02
EP0549617B1 (de) 1996-03-27
DE69118389D1 (de) 1996-05-02

Similar Documents

Publication Publication Date Title
ATE135918T1 (de) Verbesserte vakzinzusammensetzung
DE3852761D1 (de) Saponin-hilfsmittel.
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
NO943920L (no) Vaksineadjuvans
FI970799A (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
NO975366L (no) Vaksine sammensetning inneholdende polyribosylribitol fosfat og fremgangsmåte for fremstilling derav
DK0789590T3 (da) Chitosaninduceret immunforstærkning
ATE173936T1 (de) Impfstoffzusammensetzungen
GR3018660T3 (en) Nematode vaccine.
RU93005000A (ru) Композиция вакцин, способ ее получения, способ исключения иммунной реакции
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
RU92016460A (ru) Вакцинная композиция, способ индукции иммунной реакции
DK0570682T3 (da) Syntetiske lipid-A-glycoconjugat-antigener til anvendelse i vacciner
DE69130953T2 (de) Immunverstärkung von impfstoffen, besonders von impfstoffen gegen schweinepleuropneumonie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee